Immutep Ltd at Jefferies London Healthcare Conference Transcript
Welcome to the -- one of the afternoon sessions of the Jefferies healthcare conference here in London. My name's Dave Stanton. I'm part of the Australian healthcare research team. We're delighted to have Marc Voigt, CEO of Immutep, here with us today. So just a little bit about Immutep. Immutep's eftilagimod alpha is a prospective cancer drug that continues to progress through clinical trials.
It's a version of the LAG-3 immune checkpoint. And acts as an antigen-presenting cell activator, effectively increasing the number of relevant immune cells and potentially leading to destruction of tumors by immune cells when used in combination with conventional immune checkpoint inhibitors or chemotherapy.
So, as you can see here, the format today is a presentation. So, Marc, over to you and thank you very much.
Yeah. Thank you, Dave. And thank you to the Jefferies team for inviting us and letting us present. And good afternoon to all of you.
Try to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
